BioGend Therapeutics Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 1.350 million compared to TWD 112,000 a year ago. Operating loss was TWD 35.759 million compared to TWD 30.419 million a year ago. Net loss was TWD 38.264 million compared to TWD 32.929 million a year ago. Basic loss per share was TWD 0.38 compared to TWD 0.39 a year ago. For the half year, sales was TWD 2.438 million compared to TWD 485,000 a year ago. Operating loss was TWD 79.781 million compared to TWD 64.185 million a year ago. Net loss was TWD 85.098 million compared to TWD 70.113 million a year ago. Basic loss per share was TWD 0.85 compared to TWD 0.85 a year ago.